About

Balu Ranganathan is a highly skilled and experienced Technology Developer with a focus on breast cancer therapy and prognosis. With a Doctor of Philosophy in Bioengineering and Biomedical Engineering from Anna University, he has gained extensive knowledge in the field and has been in the industry for 4.85 years. Balu has a proven track record of developing innovative technologies for breast cancer therapy using nanomedicine. He has been involved in the development of TargetTaxanes®, a novel therapy for breast cancer that has shown promising results in preclinical trials. He has also worked on the development of multifunctional poly(d,l-lactide-co-glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by Trastuzumab for targeted chemotherapy of breast cancer, which was published in 2008. Balu has a deep understanding of big data analytics for feminine cancer diagnosis and prognosis and has worked with Palms Connect LLC, Sandy, UT-84094, USA, to develop new methods for analyzing large datasets to improve cancer diagnosis and prognosis. Currently, Balu is working as a Technology Developer at Canbrs Therapeutics Private Limited, where he is involved in the development of new breast cancer therapies. He has also worked as an entrepreneur and Technology Developer in the past, gaining valuable experience in the industry. Balu is proficient in Big Data and has a keen interest in using technology to improve cancer diagnosis and treatment. He is a highly motivated individual with a passion for innovation and a strong commitment to improving the lives of those affected by breast cancer.